EU/3/18/2066
Table of contents
About
On 24 August 2018, orphan designation (EU/3/18/2066) was granted by the European Commission to Incyte Biosciences Distribution B.V., the Netherlands, for pemigatinib for the treatment of biliary tract cancer.
Key facts
Active substance |
pemigatinib
|
Disease / condition |
Treatment of biliary tract cancer
|
Date of first decision |
24/08/2018
|
Outcome |
Positive
|
EU designation number |
EU/3/18/2066
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Incyte Biosciences Distribution B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands
E-mail: globalmedinfo@incyte.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.